Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. Ziprasidone I.M. Study Group
- PMID: 11206599
- DOI: 10.4088/jcp.v61n1208
Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. Ziprasidone I.M. Study Group
Abstract
Background: This 7-day, randomized, open-label, multicenter, international study compared the efficacy and tolerability of intramuscular (i.m.) ziprasidone with haloperidol i.m. and the transition from i.m. to oral treatment in hospitalized patients with acute psychotic agitation (related to DSM-III-R diagnoses).
Method: Patients received up to 3 days of flexible-dose ziprasidone i.m. (N = 90) or haloperidol i.m. (N = 42) followed by oral treatment to day 7. After an initial ziprasidone i.m. dose of 10 mg, subsequent i.m. doses of 5 to 20 mg could be given every 4 to 6 hours (maximum daily dose = 80 mg) if needed, followed by oral ziprasidone, 80-200 mg/day. Haloperidol i.m. doses of 2.5 to 10 mg were given on entry, followed by 2.5 to 10 mg i.m. every 4 to 6 hours (maximum daily dose = 40 mg) if needed, then by oral haloperidol, 10-80 mg/day.
Results: The mean reductions in Brief Psychiatric Rating Scale (BPRS) total, BPRS agitation items, and Clinical Global Impressions-Severity scale scores were statistically significantly greater (p < .05, p < .01, and p < .01, respectively) after ziprasidone i.m. treatment compared with haloperidol i.m. treatment. Further reductions in these scores also occurred in both groups following transition to oral treatment. Ziprasidone was associated with a lower incidence of movement disorders and a reduced requirement for anticholinergic medication during both i.m. and oral treatment compared with haloperidol. Movement disorder scale scores improved with ziprasidone i.m. and oral treatment, but deteriorated with haloperidol. Other adverse events were rare with both treatments.
Conclusion: Ziprasidone i.m. was significantly more effective in reducing the symptoms of acute psychosis and was better tolerated than haloperidol i.m., particularly in movement disorders. The transition from ziprasidone i.m. to oral ziprasidone was effective and well tolerated.
Similar articles
-
The tolerability of intramuscular ziprasidone and haloperidol treatment and the transition to oral therapy.Int Clin Psychopharmacol. 2004 Jan;19(1):9-15. doi: 10.1097/00004850-200401000-00002. Int Clin Psychopharmacol. 2004. PMID: 15101564 Clinical Trial.
-
The utility of intramuscular ziprasidone in the management of acute psychotic agitation.Ann Clin Psychiatry. 2004 Jul-Sep;16(3):145-54. doi: 10.1080/10401230490487025. Ann Clin Psychiatry. 2004. PMID: 15517847 Clinical Trial.
-
An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder.J Clin Psychopharmacol. 1998 Aug;18(4):296-304. doi: 10.1097/00004714-199808000-00009. J Clin Psychopharmacol. 1998. PMID: 9690695 Clinical Trial.
-
Best clinical practice with ziprasidone IM: update after 2 years of experience.CNS Spectr. 2005 Sep;10(9):1-15. doi: 10.1017/s1092852900025487. CNS Spectr. 2005. PMID: 16247923 Review.
-
Spotlight on ziprasidone in schizophrenia and schizoaffective disorder.CNS Drugs. 2002;16(9):645-52. doi: 10.2165/00023210-200216090-00005. CNS Drugs. 2002. PMID: 12153335 Review.
Cited by
-
Efficacy and Safety of Ziprasidone Injection vs Haloperidol Injection for Agitation in Patients with Acute Schizophrenia.Alpha Psychiatry. 2025 Apr 28;26(2):40032. doi: 10.31083/AP40032. eCollection 2025 Apr. Alpha Psychiatry. 2025. PMID: 40352076 Free PMC article.
-
New treatments for agitation.Psychiatr Q. 2004 Fall;75(3):197-213. doi: 10.1023/b:psaq.0000031791.53142.85. Psychiatr Q. 2004. PMID: 15335224
-
Adverse effects of atypical antipsychotics in the elderly: a review.Drugs Aging. 2006;23(12):937-56. doi: 10.2165/00002512-200623120-00002. Drugs Aging. 2006. PMID: 17154659 Review.
-
QT Interval Prolongation Associated with Intramuscular Ziprasidone in Chinese Patients: A Case Report and a Comprehensive Literature Review with Meta-Analysis.Case Rep Psychiatry. 2014;2014:489493. doi: 10.1155/2014/489493. Epub 2014 Nov 4. Case Rep Psychiatry. 2014. PMID: 25530900 Free PMC article.
-
Ziprasidone: a review of its use in schizophrenia and schizoaffective disorder.CNS Drugs. 2006;20(12):1027-52. doi: 10.2165/00023210-200620120-00006. CNS Drugs. 2006. PMID: 17140281 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical